Cellulaze™, a minimally-invasive laser technology designed for the long-term reduction of cellulite, has received clearance in the EU, Canada, Korea & Australia. In the United States the US Food and Drug Administration reviewed and cleared the device in early 2012.
Cellulite is a stubborn problem troubling over 80% of women. Typically a variety of treatments have traditionally been employed to treat cellulite, with varying results. With a reported 93% satisfaction rate, Cellulaze attacks the very structure of cellulite and is proven to reduce its appearance after one simple treatment.
How it Works
A small tube, about the size of the tip of a pen, is inserted directly under the skin. Laser energy is then directed to the treatment area, targeting the fibrous bands that pull down on the skin and create the “bumpy” appearance of cellulite.
What to Expect
Cellulaze is performed under local anesthesia with a small cannula being inserted under the skin. Patients report only minimal discomfort or a feeling of light pressure during the procedure. Many patients also notice a stimulation in collagen growth for thicker, tighter looking skin. Following treatment, some soreness may occur but you will be able to return to normal activities in 1-2 days. Improvements can be seen right away with optimal results stabilizing within 3-6 months after treatment.
Are you an Ideal Candidate?
Patients who have experienced the best results are not significantly overweight but have moderate cellulite on their thighs.
About its Developers
Laser energy has been used for years to smooth skin and remove fat cells. Cynosure, Inc. (NASDAQ: CYNO), marker of Cellulaze™, has had prior success with its SmartLipo™ device, a minimally-invasive fat reduction device. Cynosure is a leader in the development and distribution of laser and light-based technologies for the improvement of aesthetic issues.